COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

Sinovac - CoronaVac vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-07-22)

Evidence profile
2021-07-26

Summary of findings
2021-07-26

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04651790
Sinovac Research and Development Co., Ltd
Bueno S, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. N=434
Low
Details

Full description

NCT04551547
Sinovac Research and Development Co., Ltd
Han B, SSRN, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 1.5 mcg D0/28

Adjuvant D0/28

CoronaVac 3.0 mcg D0/28

RCT
Phase 1/2
Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. N=552
Low
Details

Full description

NCT04456595
Sinovac Research and Development Co., Ltd
Palacios R, SSRN, 2021
PROFISCOV

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. N=12408
Some concerns
Details

Full description

NCT04582344
Sinovac Research and Development Co., Ltd
Tanriover M, Lancet , 2021
New

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Adjuvant

RCT
Phase 3
Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey N=10218
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd
Wu Z, Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 1.5mcg D0/28

CoronaVac

CoronaVac 6mcg D0/28

Adjuvant

RCT
Phase 1/2
Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China N=422
Low
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 6 mcg D0/28

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/14

CoronaVac

Adjuvant

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=144
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac

CoronaVac 6 mcg D0/14

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/28

Adjuvant

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=600
Some concerns
Details

Full description